Another Phase III Study Supports Avastin Expansion To Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.
You may also be interested in...
Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA Finally Approves Avastin In First-Line Ovarian Cancer
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Roche is gearing up for a planned year-end submission of Avastin in advanced ovarian cancer in the EU after making a splash at the European Society for Medical Oncology meeting with updated data from its Phase III ICON7 study showing a progression-free survival benefit.